Rahul Goel

Rahul Goel

Auto-generated profile, based on publicly available information

Rahul Goel

Duke Univ, Sch Med, Dept Orthopaed Surg, Durham, NC USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
JDJonathan R. Danoff
Jonathan R. Danoff
RGRahul Goel
Rahul Goel
RSRyan Sutton
Ryan Sutton
MMMitchell G. Maltenfort
Mitchell G. Maltenfort
MAMatthew S. Austin
Matthew S. Austin

16 October 2019 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
RGRahul Goel
Rahul Goel
ARAlexander J. Rondon
Alexander J. Rondon
KSKiersten Sydnor
Kiersten Sydnor
KBKier Blevins
Kier Blevins
MOMichael O’mAlley
Michael O’mAlley
MAMatthew S. Austin
Matthew S. Austin
Background: The use of a tourniquet during total knee arthroplasty (TKA) is controversial. Pain and return to function are believed, by some, to be influenced by the use of a tourniquet. The hypothesis of this study was that use of a tourniquet would delay postoperative functional recovery and increase pain as compared with no tourniquet use. Methods: Two hundred patients were recruited for this prospective, double-blinded, randomized controlled trial. Patients were randomized to undergo TKA either with a tourniquet (100 patients) or without one (100 patients) and blinded to group allocation. Primary outcome measures were functional assessment testing using the Timed Up & Go (TUG) test and visual analog scale (VAS) pain scores. Secondary outcome measures included the stair-climb test, blood loss, surgical field visualization, and range of motion. Outcome measures were completed preoperatively, in the hospital, and postoperatively at a first and a second follow-up. The minimal detectable change, Student t test, Fisher exact test, and nonasymptotic chi-square analysis with an alpha of p < 0.05 were used to determine significance. Results: The no-tourniquet group had more calculated blood loss (1,148.02 mL compared with 966.64 mL; p < 0.001) and more difficulty with surgical field visualization (p < 0.0001). The tourniquet group had greater knee extension at the first follow-up (−7° compared with −9°; p = 0.044). Conclusions: Tourniquet use during TKA significantly decreases blood loss and does not adversely affect early postoperative outcomes. Tourniquet use during routine TKA is safe and effective, and concerns about deleterious effects on function and pain may not be justified. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

1 August 2018 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
JDJonathan R. Danoff
Jonathan R. Danoff
RGRahul Goel
Rahul Goel
RHR. Andrew Henderson
R. Andrew Henderson
JFJames Fraser
James Fraser
PSPeter F. Sharkey
Peter F. Sharkey

1 February 2019 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
GBGiovanni Balato
Giovanni Balato
KSKatarina Barbaric Starcevic
Katarina Barbaric Starcevic
GBGoran Bićanić
Goran Bićanić
SBStefano Bini
Stefano Bini
JCJiying Chen
Jiying Chen
ATAnastasios-Nektarios Tzavellas
Anastasios-Nektarios Tzavellas

1 November 2018 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
RGRahul Goel
Rahul Goel
PBPatrick Buckley
Patrick Buckley
ESEmily Sterbis
Emily Sterbis
JPJavad Parvizi
Javad Parvizi

1 January 2018 in The Bone & Joint Journal
Verified
Journal Article
Closed access
RGR. Goel
R. Goel
AFA. N. Fleischman
A. N. Fleischman
TTT. Tan
T. Tan
ESE. Sterbis
E. Sterbis
RHR. Huang
R. Huang
RRR. H. Rothman
R. H. Rothman
Aims: The aims of this study were to compare the efficacy of two agents, aspirin and warfarin, for the prevention of venous thromboembolism (VTE) after simultaneous bilateral total knee arthroplasty (SBTKA), and to elucidate the risk of VTE conferred by this procedure compared with unilateral TKA (UTKA). Patients and Methods: A retrospective, multi-institutional study was conducted on 18 951 patients, 3685 who underwent SBTKA and 15 266 who underwent UTKA, using aspirin or warfarin as VTE prophylaxis. Each patient was assigned an individualised baseline VTE risk score based on a system using the Nationwide Inpatient Sample. Symptomatic VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT), were identified in the first 90 days post-operatively. Statistical analyses were performed with logistic regression accounting for baseline VTE risk. Results: The adjusted incidence of PE following SBTKA was 1.0% (95% confidence interval (CI) 0.86 to 1.2) with aspirin and 2.2% (95% CI 2.0 to 2.4) with warfarin. Similarly, the adjusted incidence of VTE following SBTKA was 1.6% (95% CI 1.1 to 2.3) with aspirin and 2.5% (95% CI 1.9 to 3.3) with warfarin. The risk of PE and VTE were reduced by 66% (odds ratio (OR) 0.44, 95% CI 0.25 to 0.78) and 38% (OR 0.62, 95% CI 0.38 to 1.0), respectively, using aspirin. In addition, the risk of PE was 204% higher for patients undergoing SBTKA relative to those undergoing UTKA. For each ten-point increase in baseline VTE risk, the risk of PE increased by 25.5% for patients undergoing SBTKA compared with 10.5% for those undergoing UTKA. Patients with a history of myocardial infarction or peripheral vascular disease had the greatest increase in risk from undergoing SBTKA instead of UTKA. Conclusion: Aspirin is more effective than warfarin for the prevention of VTE following SBTKA, and serves as the more appropriate agent for VTE prophylaxis for patients in all risk categories. Furthermore, patients undergoing SBTKA are at a substantially increased risk of VTE, even more so for those with significant underlying risk factors. Patients should be informed about the risks associated with undergoing SBTKA. Cite this article: Bone Joint J 2018;100-B(1 Supple A):68–75.